IKZF Family

IKZF Family製品

All (8)
IKZF Family阻害剤 (4)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S1029	Lenalidomide (CC-5013)	Lenalidomide is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.	Signal Transduct Target Ther, 2025, 10(1):29 Nat Commun, 2025, 16(1):3800 Cell Rep Med, 2025, S2666-3791(25)00102-8
S2881	Homo-PROTAC cereblon degrader 1	Homo-PROTAC cereblon degrader 1 (OUN20985) is a potent and efficient cereblon (CRBN) degrader with minimal effects on IKZF1 and IKZF3.	Antimicrob Agents Chemother, 2025, 69(1):e0117224 Eur J Immunol, 2021, 10.1002/eji.202149269
E1381	NX-2127	NX-2127 is a unique, potent inhibitor of BTK that prevents its functions by catalyzing the ubiquitylation and proteasomal degradation of BTK rather than via direct binding. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells.
E1184	CFT7455	CFT7455 is an orally active zinc finger transcription factors (IKZF1) (Ikaros) and IKZF3 (Aiolos) degrader. It binds with high affinity to the cereblon E3 ligase (Kd of 0.9 nM). It is used in the treatment of multiple myeloma & non-Hodgkin’s lymphoma.
E4669^New	KT-413	KT-413 (IRAK degrader-1, zomiradomide) is a dual-function PROTAC molecule and a potent degrader of interleukin-1 receptor associated kinase 4 (IRAK4) and the transcription factors Ikaros and Aiolos by acting as both a heterobifunctional degrader and a molecular glue. It can be used in research for developing therapies targeting the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).
E6029	Lenalidomide hemihydrate	Lenalidomide hemihydrate (CC-5013 hemihydrate) is a potent inhibitor of TNF-alpha with a IC50 of 13 nM. It induces tyrosine phosphorylation of CD28 on T cells, which subsequently activates NF-κB. It acts as a ligand for the ubiquitin E3 ligase cereblon (CRBN), leading to the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 through the CRBN-CRL4 ubiquitin ligase complex.
E1204	NVP-DKY709	NVP-DKY709 is a potent IKZF2 inhibitor for the treatment of cancers.
E4724^New	MGD-28	MGD-28 is a potent and orally active degrader of Cereblon (CRBN)-dependent IKAROS proteins. It effectively degrades IKZF1 (DC50 = 3.8 nM), IKZF2 (DC50 = 56.3 nM), and IKZF3 (DC50 = 7.1 nM). It demonstrates significant antiproliferative potency across various hematologic cancer cell lines.
S2881	Homo-PROTAC cereblon degrader 1	Homo-PROTAC cereblon degrader 1 (OUN20985) is a potent and efficient cereblon (CRBN) degrader with minimal effects on IKZF1 and IKZF3.	Antimicrob Agents Chemother, 2025, 69(1):e0117224 Eur J Immunol, 2021, 10.1002/eji.202149269
E1381	NX-2127	NX-2127 is a unique, potent inhibitor of BTK that prevents its functions by catalyzing the ubiquitylation and proteasomal degradation of BTK rather than via direct binding. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells.
E6029	Lenalidomide hemihydrate	Lenalidomide hemihydrate (CC-5013 hemihydrate) is a potent inhibitor of TNF-alpha with a IC50 of 13 nM. It induces tyrosine phosphorylation of CD28 on T cells, which subsequently activates NF-κB. It acts as a ligand for the ubiquitin E3 ligase cereblon (CRBN), leading to the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 through the CRBN-CRL4 ubiquitin ligase complex.
E1204	NVP-DKY709	NVP-DKY709 is a potent IKZF2 inhibitor for the treatment of cancers.
E4669^New	KT-413	KT-413 (IRAK degrader-1, zomiradomide) is a dual-function PROTAC molecule and a potent degrader of interleukin-1 receptor associated kinase 4 (IRAK4) and the transcription factors Ikaros and Aiolos by acting as both a heterobifunctional degrader and a molecular glue. It can be used in research for developing therapies targeting the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).
E4724^New	MGD-28	MGD-28 is a potent and orally active degrader of Cereblon (CRBN)-dependent IKAROS proteins. It effectively degrades IKZF1 (DC50 = 3.8 nM), IKZF2 (DC50 = 56.3 nM), and IKZF3 (DC50 = 7.1 nM). It demonstrates significant antiproliferative potency across various hematologic cancer cell lines.